Company Encyclopedia
View More
name
HPGC
600664.SH
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron vitamin B12 oral solutions, ceftriaxone sodium injections, Qufenggutong gel cream, GNC Vitapak nutrition package, lacidipine tablets, GNC fish oil, GNC children's liquid calcium magnesium zinc IV, and penicillin and cephalosporin antibiotic preparations. The company sells its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, Puxue, Hayao, and Shiyitang brands.
3.165 T
600664.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking107/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE8.26%B
    • Profit Margin2.82%C
    • Gross Margin24.40%C
  • Growth ScoreD
    • Revenue YoY-1.72%D
    • Net Profit YoY-26.73%D
    • Total Assets YoY-1.31%D
    • Net Assets YoY7.69%B
  • Cash ScoreB
    • Cash Flow Margin3549.04%A
    • OCF YoY-1.72%D
  • Operating ScoreA
    • Turnover1.12A
  • Debt ScoreC
    • Gearing Ratio54.49%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HPGC released its performance for the first three quarters, with a net profit attributable to the parent company of 329 million yuan, a year-on-year decrease of 35.35%

    According to the Zhitong Finance APP, HPGC disclosed its third-quarter report for 2025. The company's revenue for the first three quarters reached 12.021 billion yuan, a year-on-year decrease of 1.92%; the net profit attributable to shareholders was 329 million yuan, a year-on-year decrease of 35.35%; the net profit excluding non-recurring gains and losses was 289 million yuan, a year-on-year decrease of 38.56%; and the basic earnings per share were 0.13 yuan

    Zhitong·
    SH
    600664
    -1.89%
    Zhitong·
    SH
    600664
    -1.89%

    HPGC: Lercanidipine tablets pass the consistency evaluation for generic drugs

    HPGC announced that its subsidiary Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, confirming that Lacidipine tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Lacidipine is an efficient calcium ion antagonist primarily used for dilating peripheral small arteries and lowering blood pressure, suitable for the treatment of hypertension

    Zhitong·
    SH
    600664
    -1.89%
    Zhitong·
    SH
    600664
    -1.89%

    HPGC released its performance for the first half of the year, with a net profit attributable to the parent company of 260 million yuan, a year-on-year decrease of 24.37%

    According to the Zhitong Finance APP, HPGC released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 8.125 billion yuan, a year-on-year decrease of 0.21%. The net profit attributable to shareholders of the listed company was 260 million yuan, a year-on-year decrease of 24.37%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 244 million yuan, a year-on-year decrease of 21.71%. The basic earnings per share were 0.1 yuan

    Zhitong·
    SH
    600664
    -1.89%
    Zhitong·
    SH
    600664
    -1.89%

    HPGC: Norfloxacin capsules (0.1g) passed the consistency evaluation of quality and efficacy for generic drugs

    HPGC announced that its norfloxacin capsules (0.1g) have passed the consistency evaluation of quality and efficacy for generic drugs by the National Medical Products Administration. This approval will provide greater support for the drug in areas such as medical insurance reimbursement and procurement by medical institutions, helping to expand market share and enhance competitiveness, while also accumulating experience for the company's future generic drug products

    Zhitong·
    SH
    600664
    -1.89%
    Zhitong·
    SH
    600664
    -1.89%

    HPGC: Wholly-owned subsidiary signs "Technology Transfer Contract"

    HPGC announced that its wholly-owned subsidiary, HPGC Biotechnology Co., Ltd., has signed a "Technology Transfer Agreement" with Shanghai Bozhi Research and Development Co., Ltd. to purchase the clinical approval for Dapoxetine tablets and to collaborate on subsequent development and market launch matters. The total amount of the contract is expected to be 44.8 million yuan, with funding sourced from HPGC Biotechnology's own funds. The transaction does not constitute a related party transaction or a major asset restructuring and does not require submission for shareholder meeting approval

    Zhitong·
    SH
    600664
    -1.89%
    Zhitong·
    SH
    600664
    -1.89%
    © 2025 Longbridge｜Disclaimer